WSJA bill that would ban makers of brand-name pharmaceuticals from paying to stop cheaper, generic drugs from hitting the market has the support of key lawmakers ahead of a House subcommittee hearing on the matter set for Tuesday.
The bill is aimed at stopping payments lawmakers characterize as anticompetitive and costing consumers and the federal government billions of dollars a year by forcing people to continue to pay for higher-priced, brand-name drugs.
My friends, it is legal (for reasons I find unreasonable) for a drug company to pay a competitor to delay release of generic drugs that compete with their drugs. So drug company A can pay drug company B to not release a drug that would cut a person's medication costs by three to five times.
Physicians put up with far too much regulation and drug companies still reign in the cash...at least for now.
Best Regards,
John Di Saia MD
My friends, it is legal (for reasons I find unreasonable) for a drug company to pay a competitor to delay release of generic drugs that compete with their drugs. So drug company A can pay drug company B to not release a drug that would cut a person's medication costs by three to five times.
Physicians put up with far too much regulation and drug companies still reign in the cash...at least for now.
Best Regards,
John Di Saia MD